BioPharm Business News and Perspectives

Tuesday, April 27, 2010 DePuy Spine Launches Expedium Vertebral Body Derotation Instrument Set
The set is designed to help surgeons correct spinal alignment and decrease rib rotation in patients with scoliosis...

Wednesday, April 21, 2010 GSK and Human Genome's Lupus Drug Fails to Meet Secondary Endpoint in Phase III Trial
Effects of the lupus drug Benlysta (belimumab) appear to wane over time...

Wednesday, April 07, 2010 Pfizer Predicts "Golden Age of Drug Discovery"
Pfizer is working on drugs to treat pain, inflammation, cancer, and Alzheimer's disease, some of which they predict will be mega sellers...

Monday, March 15, 2010 Roche Suspends Experimental Arthritis Drug Study
Risks were found to outweigh potential benefits in the study of ocrelizumab after cases of serious infections led to several deaths...

Thursday, March 11, 2010 AstraZeneca in a Deal with Torrent Pharmaceuticals to Market Generics
The UK drugmaker will market 18 of Torrent's drugs in 9 emerging economies, marking AstraZeneca's first generic-drug partnership...

Wednesday, February 17, 2010 AstraZeneca to Enter the RA Market
AstraZeneca is entering the rheumatoid arthritis (RA) market by gaining rights to Rigel’s RA drug...

Thursday, February 11, 2010 Merck Settles Vioxx Lawsuits
Merck & Co. has agreed to settle lawsuits over their withdrawn painkiller Vioxx with a strengthening of safety procedures, change of leadership, and payment of legal fees...

Tuesday, February 02, 2010 UCB to Exit the Primary Care Market in the US
Instead, the company plans to focus on becoming a patient-centric global biopharmaceutical leader...

Monday, February 01, 2010 CP-690,550, Pfizer's Oral JAK Inhibitor, Demonstrates Response in Patients with Active Rheumatoid Arthritis
Pfizer’s oral JAK Inhibitor CP-690,550 shows efficacy at improving the pain, function, and health status of RA patients...

Tuesday, January 26, 2010 FDA Approves Tocilizumab for Refractory RA
Tocilizumab (Actemra) has been approved for adults with moderate-to-severe RA who have not achieved adequate response with other TNF therapies...